Post-Marketing Surveillance of Polatuzumab Vedotin: A Disproportionality Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Muscara, Claudia [1 ]
Allegra, Alessandro [2 ]
Tuccoli, Marco [3 ]
Flaccavento, Alessandra [4 ]
Cutroneo, Paola Maria [1 ]
机构：
[1] Univ Hosp Messina, Sicilian Reg Pharmacovigilance Ctr, Clin Pharmacol Unit, Messina, Italy
[2] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Hematol Unit, Messina, Italy
[3] Univ Hosp Pisa, Unit Adverse Drug React Monitoring, Pisa, Italy
[4] Univ Pisa, Dept Clin & Expt Med Sect Pharmacol & Pharmacovig, Pisa, Italy
来源：
DRUG SAFETY | 2024年 / 47卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
210
引用
收藏
页码：1408 / 1408
页数：1
相关论文
共 50 条
  • [31] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [32] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [33] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [34] A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database
    Cui, Shichao
    Li, Li
    Liu, Wensheng
    Zhao, Bin
    Zhong, Xingming
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2024, 57
  • [35] Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database
    Nair, Harsha Prakash
    Kulkarni, Apoorva Rachana
    Eswaran, Maheswari
    Subeesh, Viswam
    ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (01) : 1 - 4
  • [36] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [37] Adverse event profiles of CDK4/6 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
    Tian, Xiaojiang
    Chen, Lin
    Chen, Yonghong
    Zhang, Ni
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [38] Novel Adverse Event of Atezolizumab: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Ahmed, Abdul Mannan Faruk
    Maheswari, Eswaran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 306 - 306
  • [39] Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System
    Raschi, E.
    Fusaroli, M.
    Forni, M.
    Goldman, A.
    Cicero, A. F. G.
    Poluzzi, E.
    Ponti, F. D.
    DRUG SAFETY, 2022, 45 (10) : 1287 - 1288
  • [40] Post-marketing safety of checkpoint inhibitors: analysis of the FDA adverse event reporting system
    Elias, Rawad
    Rider, Jennifer
    Rahma, Osama
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345